Mumbai, 22 July 2025 — In a landmark achievement for India's life sciences and green chemistry sector, Godavari Biorefineries Limited (GBL), through its biotech division Sathgen Therapeutics, has received a Chinese patent for its breakthrough anti-cancer molecule HYDROXY-1,4-NAPHTHALENEDIONE. The patent was granted by the China National Intellectual Property Administration (CNIPA), a significant validation of GBL’s innovation in cancer therapeutics.

The patented compound belongs to a novel class of molecules which have exhibited strong inhibitory effects on cancer and cancer stem cells in in-vitro studies. These molecules have demonstrated potent results across multiple cancer types, notably breast and prostate cancers, indicating a wide therapeutic potential.

Speaking on the occasion, Dr. Sangeeta Srivastava, Executive Director of Godavari Biorefineries, said, “Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences. This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide.”

A Strategic Leap into Global Biotech

This international recognition comes at a time when GBL is deepening its commitment to translational research in high-impact areas such as oncology and virology. Through Sathgen Therapeutics, the company is advancing clinical-stage therapies targeting both cancer and viral diseases. With global patent protection for its lead molecule, the company is aiming to build partnerships and expand its research collaborations worldwide.

The molecule HYDROXY-1,4-NAPHTHALENEDIONE is currently undergoing clinical trials, and the results so far have been promising. This progress positions GBL among the few Indian companies making a significant mark in innovative drug development on the global stage.

Export-Oriented, Innovation-Driven

Godavari Biorefineries already exports to over 20 countries and has deep linkages with international R&D institutions. The Chinese patent will open new avenues in the vast Chinese pharmaceutical market and strengthen the company’s IP portfolio, especially in Asia. The company is also exploring licensing opportunities and strategic alliances to commercialise the molecule post-clinical validation.

GBL’s achievements also underscore a shift in India’s biotech narrative—from generic manufacturing to original research and patented therapies. The company is determined to lead this change, combining green chemistry, biotechnology, and clinical medicine under one integrated vision.

A Company Rooted in Science and Sustainability

Founded with the aim of providing sustainable solutions through renewable chemistry, Godavari Biorefineries Limited has steadily evolved into a diversified group with strong capabilities in biofuels, green chemicals, and now life sciences. Listed on both BSE (544279) and NSE (GODAVARIB), GBL continues to focus on circular economy principles and value-added innovation.

Their biotech arm, Sathgen Therapeutics, represents the company's foray into high-impact health research, addressing challenges like cancer with next-gen therapeutics developed using advanced scientific models and rigorous validation protocols.

What This Means for India’s Biotech Ecosystem

This Chinese patent is more than a corporate milestone—it represents the emergence of Indian biotech research as a competitive force on the global stage. With increasing support from global IP institutions and growing success in clinical pipelines, Indian innovators like Godavari Biorefineries are setting new standards in biopharma excellence.

The move is expected to boost investor confidence, attract global partners, and enhance India's reputation as a hub for world-class biotech research and development.

Looking Ahead

The journey from laboratory to clinic is challenging, but GBL’s strategic roadmap and consistent execution offer hope. With a team of dedicated researchers and visionary leadership, the company is poised to deliver next-generation cancer therapeutics that are both effective and accessible.

GBL’s commitment to scientific integrity, global compliance, and patient-focused innovation continues to be the bedrock of its future strategies. The newly secured Chinese patent only adds to the momentum, reaffirming the company’s ambition to transform cancer treatment paradigms across borders.

The Upcoming IPOs in this week and coming weeks are Sellowrap Industries, Repono, Shanti Gold International, Indiqube Spaces, GNG Electronics, Brigade Hotel Ventures, Patel Chem Specialities, TSC India, NSDL.

The Current active IPO are Monarch Surveyors & Engineering Consultants, Swastika Castal, Savy Infra.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.